{"nctId":"NCT02630992","briefTitle":"Reduced Clavulanate Formulation of Amoxicillin-Clavulanate in Children 6-23 Months With Acute Otitis Media","startDateStruct":{"date":"2015-12"},"conditions":["Acute Otitis Media"],"count":112,"armGroups":[{"label":"amoxicillin-clavulanate potassium","type":"EXPERIMENTAL","interventionNames":["Drug: Amoxicillin-Clavulanate potassium"]}],"interventions":[{"name":"Amoxicillin-Clavulanate potassium","otherNames":["Augmentin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age range: 6 to 23 months\n* Evidence of AOM\n* Recent (within 48 hours) onset of signs and symptoms.\n* Middle ear effusion evidenced by the presence of at least 2 of the following: decreased or absent mobility of the tympanic membrane (TM), yellow of white discoloration of the TM, and/or opacification of the TM\n* Acute inflammation evidenced by one of the following: 1+ bulging of the TM with either intense erythema or otalgia or 2+ or 3+ bulging of the TM\n\nExclusion Criteria:\n\n* Toxic appearance (capillary refill \\>3 seconds, systolic blood pressure \\<60 mm Hg)\n* Inpatient hospitalization\n* Clinical or anatomical characteristics that might obscure response to treatment (e.g., tympanostomy tubes in place, cleft palate, Down syndrome)\n* Sensorineural hearing loss (unilateral or bilateral)\n* Allergy to amoxicillin or amoxicillin clavulanate\n* Recent treatment of AOM within the last 14 days","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Months","maximumAge":"23 Months","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Distribution of Participants Receiving Formulation 1 for Whom Protocol-Defined Diarrhea (PDD) Was Reported and Associated With Study Product","description":"Participants receiving formulation 1 were administered amoxicillin-clavulanate potassium containing a reduced concentration of clavulanate potassium, 600 mg/21.5 mg/5 mL (a ratio of 28:1), administered at 90/3.2 mg/kg/day in two divided doses for 10 days.\n\nProtocol-defined diarrhea is defined as the occurrence of three or more watery stools in 1 day or two watery stools daily for 2 consecutive days and is limited to events associated with study product.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null}]}]}]},{"type":"PRIMARY","title":"The Distribution of Participants Receiving Formulation 2 for Whom Protocol-Defined Diarrhea (PDD) Was Reported and Associated With Study Product","description":"Participants receiving formulation 2 were administered amoxicillin-clavulanate potassium containing a reduced concentration of clavulanate potassium, 600 mg/21.5 mg/5 mL (a ratio of 28:1), administered at 80/2.85 mg/kg/day in two divided doses for 10 days.\n\nProtocol-defined diarrhea is defined as the occurrence of three or more watery stools in 1 day or two watery stools daily for 2 consecutive days and is limited to events associated with study product.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]}]},{"type":"PRIMARY","title":"The Distribution of Participants Receiving Formulation 1 for Whom Diaper Dermatitis Was Reported and Associated With Study Product","description":"Participants receiving formulation 1 were administered amoxicillin-clavulanate potassium containing a reduced concentration of clavulanate potassium, 600 mg/21.5 mg/5 mL (a ratio of 28:1), administered at 90/3.2 mg/kg/day in two divided doses for 10 days.\n\nDiaper dermatitis is defined as dermatitis in the diaper area calling for prescription of a topical antifungal agent and is limited to events associated with study product.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null}]}]}]},{"type":"PRIMARY","title":"The Distribution of Participants Receiving Formulation 2 for Whom Diaper Dermatitis Was Reported and Associated With Study Product","description":"Participants receiving formulation 2 were administered amoxicillin-clavulanate potassium containing a reduced concentration of clavulanate potassium, 600 mg/21.5 mg/5 mL (a ratio of 28:1), administered at 80/2.85 mg/kg/day in two divided doses for 10 days.\n\nDiaper dermatitis is defined as dermatitis in the diaper area calling for prescription of a topical antifungal agent and is limited to events associated with study product..","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null}]}]}]},{"type":"SECONDARY","title":"The Distribution of Participants Receiving Formulation 1 Categorized as Treatment Failure (TF) at or Before the End-of-Treatment Visit","description":"Participants receiving formulation 1 were administered amoxicillin-clavulanate potassium containing a reduced concentration of clavulanate potassium, 600 mg/21.5 mg/5 mL (a ratio of 28:1), administered at 90/3.2 mg/kg/day in two divided doses for 10 days.\n\nTreatment failure is defined as substantial persistence or worsening of symptoms specifically attributable to AOM or of otoscopic signs of acute inflammation (bulging of the TM or intense erythema) after 72 hours from the initial AOM, such that additional antimicrobial therapy is deemed advisable. Clinical success is defined as complete or substantial resolution of symptoms specifically attributable to AOM for 48 hours and of otoscopic signs of acute inflammation (bulging of the TM or intense erythema), with or without persistence of middle-ear effusion, such that no additional antibiotic therapy is deemed advisable.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"31","spread":null}]}]}]},{"type":"SECONDARY","title":"The Distribution of Participants Receiving Formulation 2 Categorized as Treatment Failure (TF) at or Before the End-of-Treatment Visit","description":"Participants receiving formulation 2 were administered amoxicillin-clavulanate potassium containing a reduced concentration of clavulanate potassium, 600 mg/21.5 mg/5 mL (a ratio of 28:1), administered at 80/2.85 mg/kg/day in two divided doses for 10 days.\n\nTreatment failure is defined as substantial persistence or worsening of symptoms specifically attributable to AOM or of otoscopic signs of acute inflammation (bulging of the TM or intense erythema) after 72 hours from the initial AOM, such that additional antimicrobial therapy is deemed advisable. Clinical success is defined as complete or substantial resolution of symptoms specifically attributable to AOM for 48 hours and of otoscopic signs of acute inflammation (bulging of the TM or intense erythema), with or without persistence of middle-ear effusion, such that no additional antibiotic therapy is deemed advisable.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null}]}]}]},{"type":"SECONDARY","title":"The Distribution of Participants Receiving Formulation 1 Demonstrating Resolution of Acute Otitis Media (AOM) and Substantial Improvement of Symptoms That Would Allow Discontinuing Therapy at the Day 7 Visit","description":"Participants receiving formulation 1 were administered amoxicillin-clavulanate potassium containing a reduced concentration of clavulanate potassium, 600 mg/21.5 mg/5 mL (a ratio of 28:1), administered at 90/3.2 mg/kg/day in two divided doses for 10 days.\n\nAn assessment of participants was conducted at the day 7 visit using the AOM-SOS scale.\n\nThe AOM-SOS scale measures five discrete items: tugging of ears, crying, irritability, difficulty sleeping, and fever. Parents are asked to rate these symptoms in comparison with the child's usual state, as \"none,\" \"a little,\" or \"a lot,\" with corresponding scores of 0, 1, and 2. Thus, total scores range from 0 to 10, with higher scores indicating greater severity of symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null}]},{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"The Distribution of Participants Receiving Formulation 2 Demonstrating Resolution of Acute Otitis Media (AOM) and Substantial Improvement of Symptoms That Would Allow Discontinuing Therapy at the Day 7 Visit","description":"Participants receiving formulation 2 were administered amoxicillin-clavulanate potassium containing a reduced concentration of clavulanate potassium, 600 mg/21.5 mg/5 mL (a ratio of 28:1), administered at 80/2.85 mg/kg/day in two divided doses for 10 days.\n\nAn assessment of participants was conducted at the day 7 visit using the AOM-SOS scale.\n\nThe AOM-SOS scale measures five discrete items: tugging of ears, crying, irritability, difficulty sleeping, and fever. Parents are asked to rate these symptoms in comparison with the child's usual state, as \"none,\" \"a little,\" or \"a lot,\" with corresponding scores of 0, 1, and 2. Thus, total scores range from 0 to 10, with higher scores indicating greater severity of symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null}]},{"measurements":[{"groupId":"OG000","value":"31","spread":null}]}]}]},{"type":"SECONDARY","title":"The Mean Score Representing the Parent or Guardian's Level of Satisfaction With Therapy for Participants Receiving Formulation 1","description":"Participants receiving formulation 1 were administered amoxicillin-clavulanate potassium containing a reduced concentration of clavulanate potassium, 600 mg/21.5 mg/5 mL (a ratio of 28:1), administered at 90/3.2 mg/kg/day in two divided doses for 10 days.\n\nThe parent or guardian will answer a questionnaire regarding their satisfaction with the therapy their child received. The responses 'very dissatisfied', 'somewhat dissatisfied', 'neither satisfied nor dissatisfied', 'somewhat satisfied' and 'very satisfied' correspond to scores of 1, 2, 3, 4, and 5, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.69","spread":"0.72"}]}]}]},{"type":"SECONDARY","title":"The Mean Score Representing the Parent or Guardian's Level of Satisfaction With Therapy for Participants Receiving Formulation 2","description":"Participants receiving formulation 2 were administered amoxicillin-clavulanate potassium containing a reduced concentration of clavulanate potassium, 600 mg/21.5 mg/5 mL (a ratio of 28:1), administered at 80/2.85 mg/kg/day in two divided doses for 10 days.\n\nThe parent or guardian will answer a questionnaire regarding their satisfaction with the therapy their child received. The responses 'very dissatisfied', 'somewhat dissatisfied', 'neither satisfied nor dissatisfied', 'somewhat satisfied' and 'very satisfied' correspond to scores of 1, 2, 3, 4, and 5, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.75","spread":"0.76"}]}]}]},{"type":"SECONDARY","title":"Distribution of Population Plasma Concentration of Amoxicillin According to Time For Participants Receiving Formulation 1","description":"Participants receiving formulation 1 were administered amoxicillin-clavulanate potassium containing a reduced concentration of clavulanate potassium, 600 mg/21.5 mg/5 mL (a ratio of 28:1), administered at 90/3.2 mg/kg/day in two divided doses for 10 days.\n\nPlasma concentration of amoxicillin 45 mg/kg/dose was measured.\n\nData points up to 4 hours with a standard deviation of 0 indicate that the assessment was available for only one child.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.36","spread":"10.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.3","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.42","spread":"5.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.07","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.78","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.39","spread":"8.33"}]}]}]},{"type":"SECONDARY","title":"Distribution of Population Plasma Concentration of Amoxicillin According to Time For Participants Receiving Formulation 2","description":"Participants treated with formulation 2 were administered amoxicillin-clavulanate potassium containing a reduced concentration of clavulanate potassium, 600 mg/21.5 mg/5 mL (a ratio of 28:1), administered at 80/2.85 mg/kg/day in two divided doses for 10 days.\n\nPlasma concentration of amoxicillin 40 mg/kg/dose was measured.\n\nData points up to 4 hours with a standard deviation of 0 indicate that the assessment was available for only one child.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.63","spread":"3.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.49","spread":"1.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.76","spread":"6.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.22","spread":"7.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.00","spread":"0.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.36","spread":"1.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.52","spread":"4.54"}]}]}]},{"type":"SECONDARY","title":"Distribution of Population Plasma Concentration of Clavulanate According to Time For Participants Receiving Formulation 1","description":"Participants receiving formulation 1 were administered amoxicillin-clavulanate potassium containing a reduced concentration of clavulanate potassium, 600 mg/21.5 mg/5 mL (a ratio of 28:1), administered at 90/3.2 mg/kg/day in two divided doses for 10 days.\n\nPlasma concentration of clavulanate 1.6 mg/kg/dose was measured.\n\nData points up to 4 hours with a standard deviation of 0 indicate that the assessment was available for only one child.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1047.67","spread":"419.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2050","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"730.50","spread":"442.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"338","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"842","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"313.80","spread":"146.91"}]}]}]},{"type":"SECONDARY","title":"Distribution of Population Plasma Concentration of Clavulanate According to Time For Participants Receiving Formulation 2","description":"Participants receiving formulation 2 were administered amoxicillin-clavulanate potassium containing a reduced concentration of clavulanate potassium, 600 mg/21.5 mg/5 mL (a ratio of 28:1), administered at 80/2.85 mg/kg/day in two divided doses for 10 days.\n\nPlasma concentration of clavulanate 1.425 mg/kg/dose was measured.\n\nData points up to 4 hours with a standard deviation of 0 indicate that the assessment was available for only one child.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"407","spread":"335.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"655.50","spread":"20.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1125.33","spread":"418.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"660.16","spread":"389.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"986.95","spread":"963.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"866.00","spread":"534.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"555.50","spread":"494.53"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":112},"commonTop":["Diaper dermatitis","Protocol defined diarrhea"]}}}